• +1-646-491-9876
    • +91-20-67278686

    Search

    Smoking Addiction-Pipeline Review H1 2017

    Smoking Addiction-Pipeline Review H1 2017

    • Report Code ID: RW0001834372
    • Category Pharmaceuticals
    • No. of Pages 86
    • Publication Month Jun-17
    • Publisher Name Global Markets Direct
    Smoking Addiction - Pipeline Review, H1 2017

    Summary

    Publisher's latest Pharmaceutical and Healthcare disease pipeline guide Smoking Addiction - Pipeline Review, H1 2017, provides an overview of the Smoking Addiction (Central Nervous System) pipeline landscape.

    In smoking addiction, people experience an uncontrollable dependence on cigarettes, which on stopping will cause severe mental, emotional or physical reactions. People addicted to smoking develop tolerance to nicotine. Nicotine acts on acetylcholine receptors causing the body to react to nicotine at these receptors in the same manner as it responds to acetylcholine. This leads to alterations in the activity and physiological functions of many brain systems. This causes structural and functional changes in the brains of smokers. Upon sudden nicotine withdrawal, the brain and other parts of the body get disturbed, leading to a condition called withdrawal syndrome. The body usually takes time to function in the absence of nicotine. The effects of smoking withdrawal stem from the lack of nicotine that can be overcome by nicotine replacement therapies such as the use of nicotine patch or nicotine chewing gum.

    Report Highlights

    Publisher's Pharmaceutical and Healthcare latest pipeline guide Smoking Addiction - Pipeline Review, H1 2017, provides comprehensive information on the therapeutics under development for Smoking Addiction (Central Nervous System) , complete with analysis by stage of development, drug target, mechanism of action (MoA) , route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

    The Smoking Addiction (Central Nervous System) pipeline guide also reviews of key players involved in therapeutic development for Smoking Addiction and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase III, Phase II, Phase I, Preclinical, Discovery and Unknown stages are 1, 5, 8, 6, 3 and 1 respectively. Similarly, the Universities portfolio in Preclinical and Discovery stages comprises 2 and 1 molecules, respectively.

    Smoking Addiction (Central Nervous System) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Publisher's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

    Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

    Scope

    - The pipeline guide provides a snapshot of the global therapeutic landscape of Smoking Addiction (Central Nervous System) .
    - The pipeline guide reviews pipeline therapeutics for Smoking Addiction (Central Nervous System) by companies and universities/research institutes based on information derived from company and industry-specific sources.
    - The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
    - The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
    - The pipeline guide reviews key companies involved in Smoking Addiction (Central Nervous System) therapeutics and enlists all their major and minor projects.
    - The pipeline guide evaluates Smoking Addiction (Central Nervous System) therapeutics based on mechanism of action (MoA) , drug target, route of administration (RoA) and molecule type.
    - The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
    - The pipeline guide reviews latest news related to pipeline therapeutics for Smoking Addiction (Central Nervous System)

    Reasons to buy

    - Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
    - Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
    - Find and recognize significant and varied types of therapeutics under development for Smoking Addiction (Central Nervous System) .
    - Classify potential new clients or partners in the target demographic.
    - Develop tactical initiatives by understanding the focus areas of leading companies.
    - Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.
    - Formulate corrective measures for pipeline projects by understanding Smoking Addiction (Central Nervous System) pipeline depth and focus of Indication therapeutics.
    - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
    - Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
    Table of Contents
    List of Tables
    List of Figures
    Introduction
    Publisher Report Coverage
    Smoking Addiction - Overview
    Smoking Addiction - Therapeutics Development
    Pipeline Overview
    Pipeline by Companies
    Pipeline by Universities/Institutes
    Products under Development by Companies
    Products under Development by Universities/Institutes
    Smoking Addiction - Therapeutics Assessment
    Assessment by Target
    Assessment by Mechanism of Action
    Assessment by Route of Administration
    Assessment by Molecule Type
    Smoking Addiction - Companies Involved in Therapeutics Development
    Aradigm Corp
    Bionex Pharmaceuticals LLC
    Bioprojet SCR
    CoMentis Inc
    Embera NeuroTherapeutics Inc
    Invion Ltd
    Jeil Pharmaceutical Co Ltd
    Johnson & Johnson
    Lotus Pharmaceutical Co Ltd
    NAL Pharmaceuticals Ltd
    Pfizer Inc
    Rock Creek Pharmaceuticals, Inc.
    Selecta Biosciences Inc
    Sopharma AD
    Zynerba Pharmaceuticals Inc
    Smoking Addiction - Drug Profiles
    (metyrapone + oxazepam) - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    AKR-214 - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    amitifadine - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    Anatabine - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    AT-1001 - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    BP-1.4979 - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    cytisine - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    GTS-21 - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    JLP-1603 - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    JNJ-39393406 - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    nadolol - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    NFL-101 - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    NIC-7DT - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    nicotine - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    nicotine bitartrate - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    nicotine bitartrate - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    PF-06413367 - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    SEL-068 - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    SEL-070 - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    Small Molecule to Agonize Alpha 4Beta 2 and Alpha 6Beta 2 Neuronal Nicotinic Receptor for Smoking Cessation - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    Small Molecule to Antagonize Cannabinoid Receptor for Smoking Addiction - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    Small Molecule to Inhibit Sodium Dependent Dopamine, Noradrenaline and Serotonin Transporters for Appetite Suppression and Smoking Cessation - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    Small Molecules to Agonize Neuronal Nicotinic Acetylcholine Receptor for Smoking Cessation - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    Small Molecules to Antagonize CHRNA3 and CHRNB4 for Smoking Cessation - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    Small Molecules to Antagonize CHRNB2 and CHRNA4 for Smoking Cessation - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    URB-694 - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    Vaccine for Smoking Addiction - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    Smoking Addiction - Dormant Projects
    Smoking Addiction - Discontinued Products
    Smoking Addiction - Product Development Milestones
    Featured News & Press Releases
    May 11, 2017: Selecta Biosciences Commences Dosing in Phase 1 Clinical Trial of Nicotine Vaccine for Smoking Cessation and Relapse Prevention
    Mar 08, 2017: Achieve Life Sciences and OncoGenex Pharmaceuticals Announce Cytisine Symposium at the Annual Society for Research in Nicotine and Tobacco Conference ("SRNT")
    Oct 20, 2016: OWC Pharmaceutical Research Completes Development of Its Medical Cannabis Sublingual Tablet
    Nov 17, 2015: Invion Phase 2 Smoking Cessation Data: Results of Ongoing Analysis
    Oct 05, 2015: Invion Successfully Completes Phase 2 Study of INV102 to Aid Smoking Cessation
    Jun 29, 2015: Invion completes dosing in key phase II clinical trial of oral INV102 in smoking cessation
    Feb 02, 2015: Invion completes enrolment in its phase II trial of oral INV102 (nadolol) in smoking cessation
    Jan 19, 2015: Invion Announces Positive Interim Data from Its Phase II Clinical Trial of Oral Inv102 (nadolol) in Smoking Cessation
    Jul 01, 2014: Embera NeuroTherapeutics to Receive Grant for Clinical Trial Through New Crowd Funding Platform
    Jan 29, 2014: FDA clears path for "Smoking Cessation" clinical trial of INV102 (nadolol)
    Nov 11, 2013: Change to FDA reviewing division for smoking cessation clinical trial
    Jul 22, 2013: INVION ANNOUNCES COMMENCEMENT OF PHASE II CHRONIC BRONCHITIS CLINICAL TRIAL
    Dec 19, 2012: Invion Provides Update On INV102 Phase II Clinical Programs
    Oct 17, 2012: Nabi Biopharma's Phase II Study Of NicVAX In Combination With Varenicline Does Not Meet Primary Endpoint
    Mar 16, 2012: Embera And Collaborators Publish Paper In Psychopharmacology Supporting EMB-001 For Smoking Cessation
    Appendix
    Methodology
    Coverage
    Secondary Research
    Primary Research
    Expert Panel Validation
    Contact Us
    Disclaimer

    List of Tables

    Number of Products under Development for Smoking Addiction, H1 2017
    Number of Products under Development by Companies, H1 2017
    Number of Products under Development by Companies, H1 2017 (Contd..1) , H1 2017
    Number of Products under Development by Universities/Institutes, H1 2017
    Products under Development by Companies, H1 2017
    Products under Development by Companies, H1 2017 (Contd..1) , H1 2017
    Products under Development by Universities/Institutes, H1 2017
    Number of Products by Stage and Target, H1 2017
    Number of Products by Stage and Mechanism of Action, H1 2017
    Number of Products by Stage and Route of Administration, H1 2017
    Number of Products by Stage and Molecule Type, H1 2017
    Smoking Addiction - Pipeline by Aradigm Corp, H1 2017
    Smoking Addiction - Pipeline by Bionex Pharmaceuticals LLC, H1 2017
    Smoking Addiction - Pipeline by Bioprojet SCR, H1 2017
    Smoking Addiction - Pipeline by CoMentis Inc, H1 2017
    Smoking Addiction - Pipeline by Embera NeuroTherapeutics Inc, H1 2017
    Smoking Addiction - Pipeline by Invion Ltd, H1 2017
    Smoking Addiction - Pipeline by Jeil Pharmaceutical Co Ltd, H1 2017
    Smoking Addiction - Pipeline by Johnson & Johnson, H1 2017
    Smoking Addiction - Pipeline by Lotus Pharmaceutical Co Ltd, H1 2017
    Smoking Addiction - Pipeline by NAL Pharmaceuticals Ltd, H1 2017
    Smoking Addiction - Pipeline by Pfizer Inc, H1 2017
    Smoking Addiction - Pipeline by Rock Creek Pharmaceuticals, Inc., H1 2017
    Smoking Addiction - Pipeline by Selecta Biosciences Inc, H1 2017
    Smoking Addiction - Pipeline by Sopharma AD, H1 2017
    Smoking Addiction - Pipeline by Zynerba Pharmaceuticals Inc, H1 2017
    Smoking Addiction - Dormant Projects, H1 2017
    Smoking Addiction - Discontinued Products, H1 2017

    List of Figures

    Number of Products under Development for Smoking Addiction, H1 2017
    Number of Products under Development by Companies, H1 2017
    Number of Products under Development by Universities/Institutes, H1 2017
    Number of Products by Top 10 Targets, H1 2017
    Number of Products by Stage and Top 10 Targets, H1 2017
    Number of Products by Top 10 Mechanism of Actions, H1 2017
    Number of Products by Stage and Top 10 Mechanism of Actions, H1 2017
    Number of Products by Routes of Administration, H1 2017
    Number of Products by Stage and Routes of Administration, H1 2017
    Number of Products by Molecule Types, H1 2017
    Number of Products by Stage and Molecule Types, H1 2017
    Aradigm Corp
    Bionex Pharmaceuticals LLC
    Bioprojet SCR
    CoMentis Inc
    Embera NeuroTherapeutics Inc
    Invion Ltd
    Jeil Pharmaceutical Co Ltd
    Johnson & Johnson
    Lotus Pharmaceutical Co Ltd
    NAL Pharmaceuticals Ltd
    Pfizer Inc
    Rock Creek Pharmaceuticals, Inc.
    Selecta Biosciences Inc
    Sopharma AD
    Zynerba Pharmaceuticals Inc

    Request for Sample

    Report Url http://www.reportsweb.com//smoking-addiction-pipeline-review-h1-2017&type=sample
    Report Name
    First Name
    Last Name
    Email
    Phone
    Company
    Job Title
    Country
    Publisher
    Report Code
    Comments
     

    Inquire before Buying

    Report Url http://www.reportsweb.com//smoking-addiction-pipeline-review-h1-2017&type=buying
    Report Name
    First Name
    Last Name
    Email
    Phone
    Company
    Job Title
    Country
    Publisher
    Report Code
    Comments
     

    Inquire for Discount

    Report Url http://www.reportsweb.com//smoking-addiction-pipeline-review-h1-2017&type=discount
    Report Name
    First Name
    Last Name
    Email
    Phone
    Company
    Job Title
    Country
    Publisher
    Report Code
    Comments